<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471469</url>
  </required_header>
  <id_info>
    <org_study_id>AKF UMCN 14.17</org_study_id>
    <nct_id>NCT02471469</nct_id>
  </id_info>
  <brief_title>Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response</brief_title>
  <acronym>ILUMINATE</acronym>
  <official_title>Personalizing Enzalutamide Therapy by Understanding the Relation Between the Decrease in the Expression Profile of a Panel of Preselected microRNAs, Tumor Related mRNAs and Treatment Response in Chemotherapy Naive Patients With mCRPC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to show whether a reduction in tumor related mRNAs and a panel of
      selected miRNAS can be used to personalize enzalutamide therapy.

      Furthermore the aim is to explore the relation between drug exposure and the decrease in the
      selected biomarkers and treatment response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relation between biomarker response and therapeutic response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relation between drug exposure, biomarker and therapeutic response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide, 160mg, 40 mg soft capsules, once daily</intervention_name>
    <description>Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        chemotherapy naive patients with metastatic CRPC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients with chemotherapy naive metastatic castration resistant prostate
             cancer*

          -  Age at least 18 years

          -  Patients from who it is possible to collect blood samples

          -  Patient who are able and willing to give written informed consent prior to screening
             and enrollment

          -  Life expectancy of &gt; 6 months

          -  Measurable disease *definition of CRPC according to EAU guidelines 2014

        Exclusion Criteria:

          -  None The study objective is to explore the effect of enzalutamide on biomarker
             exposure in a group of patients treated with enzalutamide in agreement with the drug
             label. Therefore no strict exclusion criteria will be used in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nielka van Erp, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nielka van Erp, PharmD,PhD</last_name>
    <phone>00243616405</phone>
    <email>nielka.vanerp@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mette Benoist, PharmD</last_name>
    <phone>00243616405</phone>
    <email>mette.benoist@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tineke Smilde, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nielka van Erp, PharmD,PhD</last_name>
      <phone>0031243616405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Somford, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rik Somford, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>April 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
